Foreign-Trade Zone (FTZ) 35-Philadelphia, Pennsylvania, Authorization of Production Activity, Piramal Pharma Solutions (Pharmaceutical Products), Sellersville, Pennsylvania
---
identifier: "/us/fr/2022-27836"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Foreign-Trade Zone (FTZ) 35-Philadelphia, Pennsylvania, Authorization of Production Activity, Piramal Pharma Solutions (Pharmaceutical Products), Sellersville, Pennsylvania"
title_number: 0
title_name: "Federal Register"
section_number: "2022-27836"
section_name: "Foreign-Trade Zone (FTZ) 35-Philadelphia, Pennsylvania, Authorization of Production Activity, Piramal Pharma Solutions (Pharmaceutical Products), Sellersville, Pennsylvania"
positive_law: false
currency: "2022-12-22"
last_updated: "2022-12-22"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Commerce Department"
document_number: "2022-27836"
document_type: "notice"
publication_date: "2022-12-22"
agencies:
- "Commerce Department"
- "Foreign-Trade Zones Board"
fr_citation: "87 FR 78638"
fr_volume: 87
docket_ids:
- "B-37-2022"
---
# Foreign-Trade Zone (FTZ) 35—Philadelphia, Pennsylvania, Authorization of Production Activity, Piramal Pharma Solutions (Pharmaceutical Products), Sellersville, Pennsylvania
On August 19, 2022, Piramal Pharma Solutions submitted a notification of proposed production activity to the FTZ Board for its facility within FTZ 35, in Sellersville, Pennsylvania.
The notification was processed in accordance with the regulations of the FTZ Board (15 CFR part 400), including notice in the *Federal Register* inviting public comment (87 FR 52505-52506, August 26, 2022). On December 19, 2022, the applicant was notified of the FTZ Board's decision that no further review of the activity is warranted at this time. The production activity described in the notification was authorized, subject to the FTZ Act and the FTZ Board's regulations, including Section 400.14.
Dated: December 19, 2022.
Andrew McGilvray,
Executive Secretary.